Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.50.

STTK has been the topic of a number of research reports. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in Shattuck Labs by 63.2% during the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Shattuck Labs by 129.1% in the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the last quarter. State Street Corp grew its holdings in shares of Shattuck Labs by 7.8% in the third quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after acquiring an additional 55,579 shares during the period. Finally, Barclays PLC grew its holdings in shares of Shattuck Labs by 299.5% in the third quarter. Barclays PLC now owns 54,311 shares of the company’s stock worth $189,000 after acquiring an additional 40,717 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Trading Up 3.4 %

Shares of NASDAQ STTK opened at $1.20 on Monday. The stock has a market cap of $57.29 million, a price-to-earnings ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1-year low of $0.94 and a 1-year high of $11.76. The stock’s 50-day moving average is $1.24 and its 200 day moving average is $1.58.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.